查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1356794

抗結核藥物市場報告：2030 年趨勢、預測與競爭分析

Anti-Tuberculosis Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

抗結核藥物的趨勢與預測

預計2030年，全球抗結核藥物市場將達21億美元，2024年至2030年年複合成長率為7.1%。該市場的主要促進因素是患病患者病率的增加、政府組織提高結核病意識的舉措以及新興國家耐多藥和廣泛抗藥性病例的迅速增加。全球抗結核藥物市場未來性廣闊，醫院、專科診所和居家醫療市場充滿機會。

抗結核治療市場洞察

Lucintel 預測，由於結核病患者數量不斷增加以及擴大採用異煙肼治療結核病，異煙肼預計將在預測期內實現最高成長。

醫院將繼續成為該市場的最大細分市場。

由於政府措施的擴大、學名藥製造商數量的增加以及該地區醫療基礎設施的持續發展，預計亞太地區將在預測期內實現最高的成長。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要要素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些，由於材料或產品替代導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球抗結核藥物市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球抗結核藥物市場趨勢（2018-2023）與預測（2024-2030）
  • 按類型分類的全球抗結核藥物市場
    • 活動性結核病
    • 潛伏性結核病
    • 其他
  • 按藥物類別分類的全球抗結核藥物市場
    • 異煙肼
    • 利福平
    • 依三丁醇
    • 吡嗪醯胺
    • 氟喹諾酮類藥物
    • 貝達喹啉
    • 氨基糖苷類
    • 硫代醯胺
    • 環胜肽
  • 全球抗結核藥物市場（依最終用途）
    • 醫院
    • 專科診所
    • 居家護理
    • 其他

第4章 2018-2030年分地區市場趨勢及預測分析

  • 全球抗結核藥物市場區域分佈
  • 北美抗結核藥物市場
  • 歐洲抗結核藥物市場
  • 亞太地區抗結核藥物市場
  • 其他區域抗結核藥物市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按類型分類的全球抗結核藥物市場成長機會
    • 按藥物類別分類的全球抗結核藥物市場成長機會
    • 全球抗結核治療市場成長機會（依最終用途）
    • 全球抗結核藥物市場按地區成長機會
  • 全球抗結核藥物市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球抗結核藥物市場的產能
    • 全球抗結核藥物市場的合併、收購與合資
    • 認證和許可

第7章 主要企業概況

  • Lupin
  • Macleods
  • Otsuka
  • Johnson & Johnson
  • Sequella
  • Novartis
  • Akorn
  • Fresenius SE
  • Viatris
簡介目錄

Anti-Tuberculosis Therapeutics Trends and Forecast

The future of the global anti-tuberculosis therapeutics market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global anti-tuberculosis therapeutics market is expected to reach an estimated $2.1 billion by 2030 with a CAGR of 7.1% from 2024 to 2030. The major drivers for this market are growing prevalence of tuberculosis, increasing initiative from government organization towards tuberculosis awareness, and surging incidence of MDR and XDR cases in developing countries.

A more than 150-page report is developed to help in your business decisions.

Anti-Tuberculosis Therapeutics by Segment

The study includes a forecast for the global anti-tuberculosis therapeutics by type, drug classes, end use, and region.

Anti-Tuberculosis Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Active TB
  • Latent TB
  • Others

Anti-Tuberculosis Therapeutics Market by Drug Classes [Shipment Analysis by Value from 2018 to 2030]:

  • Isoniazid
  • Rifampin
  • Ethambutol
  • Pyrazinamide
  • Fluoroquinolones
  • Bedaquiline
  • Amynoglycosides
  • Thioamides
  • Cyclic Peptides
  • Others

Anti-Tuberculosis Therapeutics Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Anti-Tuberculosis Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Anti-Tuberculosis Therapeutics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies anti-tuberculosis therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the anti-tuberculosis therapeutics companies profiled in this report include-

  • Lupin
  • Macleods
  • Otsuka
  • Johnson & Johnson
  • Sequella
  • Novartis
  • Akorn
  • Fresenius Se
  • Viatris

Anti-Tuberculosis Therapeutics Market Insights

Lucintel forecasts that isoniazid is expected to witness highest growth over the forecast period due to increasing cases of tuberculosis and rising adoption of isoniazid for the treatment of tuberculosis.

Within this market, hospitals will remain the largest segment due to .

APAC is expected to witness highest growth over the forecast period due to growing government intiatives, increasing number of generic manufacturers, and on-going development of healthcare infrastructure in the region.

Features of the Global Anti-Tuberculosis Therapeutics Market

Market Size Estimates: Anti-tuberculosis therapeutics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Anti-tuberculosis therapeutics market size by type, drug classes, end use, and region. in terms of value ($B).

Regional Analysis: Anti-tuberculosis therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, drug classes, end uses, and region.s for the anti-tuberculosis therapeutics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the anti-tuberculosis therapeutics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the anti-tuberculosis therapeutics market size?

Answer: The global anti-tuberculosis therapeutics market is expected to reach an estimated $2.1 billion by 2030.

Q.2. What is the growth forecast for anti-tuberculosis therapeutics market?

Answer: The global anti-tuberculosis therapeutics market is expected to grow with a CAGR of 7.1% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the anti-tuberculosis therapeutics market?

Answer: The major drivers for this market are growing prevalence of tuberculosis, increasing initiative from government organization towards tuberculosis awareness, and surging incidence of MDR and XDR cases in developing countries.

Q.4. What are the major segments for anti-tuberculosis therapeutics market?

Answer: The future of the anti-tuberculosis therapeutics market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.

Q.5. Who are the key Anti-Tuberculosis Therapeutics Market companies?

Answer: Some of the key anti-tuberculosis therapeutics companies are as follows:

  • Lupin
  • Macleods
  • Otsuka
  • Johnson & Johnson
  • Sequella
  • Novartis
  • Akorn
  • Fresenius SE
  • Viatris

Q.6. Which anti-tuberculosis therapeutics market segment will be the largest in future?

Answer: Lucintel forecasts that isoniazid is expected to witness highest growth over the forecast period due to increasing cases of tuberculosis and rising adoption of isoniazid for the treatment of tuberculosis.

Q.7. In anti-tuberculosis therapeutics market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period due to growing government intiatives, increasing number of generic manufacturers, and on-going development of healthcare infrastructure in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the anti-tuberculosis therapeutics market by type (active TB, latent LB, and others), drug classes (isoniazid, rifampin, ethambutol, pyrazinamide, fluoroquinolones, bedaquiline, amynoglycosides, thioamides, cyclic peptides, and others), end use (hospitals, specialty clinics, homecare, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Anti-Tuberculosis Therapeutics Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Anti-Tuberculosis Therapeutics Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Anti-Tuberculosis Therapeutics Market by Type
    • 3.3.1: Active TB
    • 3.3.2: Latent TB
    • 3.3.3: Others
  • 3.4: Global Anti-Tuberculosis Therapeutics Market by Drug Classes
    • 3.4.1: Isoniazid
    • 3.4.2: Rifampin
    • 3.4.3: Ethambutol
    • 3.4.4: Pyrazinamide
    • 3.4.5: Fluoroquinolones
    • 3.4.6: Bedaquiline
    • 3.4.7: Amynoglycosides
    • 3.4.8: Thioamides
    • 3.4.9: Cyclic Peptides
  • 3.5: Global Anti-Tuberculosis Therapeutics Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Specialty Clinics
    • 3.5.3: Homecare
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Anti-Tuberculosis Therapeutics Market by Region
  • 4.2: North American Anti-Tuberculosis Therapeutics Market
    • 4.2.2: North American Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.3: European Anti-Tuberculosis Therapeutics Market
    • 4.3.1: European Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
    • 4.3.2: European Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.4: APAC Anti-Tuberculosis Therapeutics Market
    • 4.4.1: APAC Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
    • 4.4.2: APAC Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.5: ROW Anti-Tuberculosis Therapeutics Market
    • 4.5.1: ROW Anti-Tuberculosis Therapeutics Market by Drug Classes: Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, and Others
    • 4.5.2: ROW Anti-Tuberculosis Therapeutics Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Type
    • 6.1.2: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Drug Classes
    • 6.1.3: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by End Use
    • 6.1.4: Growth Opportunities for the Global Anti-Tuberculosis Therapeutics Market by Region
  • 6.2: Emerging Trends in the Global Anti-Tuberculosis Therapeutics Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Anti-Tuberculosis Therapeutics Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Anti-Tuberculosis Therapeutics Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Lupin
  • 7.2: Macleods
  • 7.3: Otsuka
  • 7.4: Johnson & Johnson
  • 7.5: Sequella
  • 7.6: Novartis
  • 7.7: Akorn
  • 7.8: Fresenius SE
  • 7.9: Viatris